S2Medical AB Class B (S2M) AI Stock Analysis

S2Medical AB Class B

(Nasdaq OMX AB:S2M)

Select Model

Rating:44Neutral

Price Target:SEK 0.01▲(177.78% Upside)

Action:reiterated

Date:08/29/26

SE:S2M receives a low overall score, primarily driven by substantial operational unprofitability and a deeply negative valuation profile. While the company benefits from a strong, zero-debt capital structure and excellent pricing power via high gross margins, these positives are completely offset by alarming net losses and cash burn. The absence of technical, earnings, and corporate event data focuses the evaluation entirely on these underlying fundamental challenges.

Positive Factors

Long-term revenue growthThe substantial multi-year revenue increase indicates that S2Medical has expanded its commercial base and product adoption. Although recent growth has weakened, the larger revenue platform provides a foundation for recovery if execution and demand stabilize.

Negative Factors

Volatile revenue trajectoryThe reversal from strong growth to declines reduces confidence in demand durability and forecasting reliability. Continued volatility could weaken operating leverage, make resource planning harder, and delay the ability to convert the expanded revenue base into consistent returns.

S2Medical AB Class B (S2M) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 6.89M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): 0.70
Revenue Growth: ―
EPS Growth: ―
Country: Sweden
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

S2Medical AB Class B Business Overview & Revenue Model

Company Description

S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical de...

S2Medical AB Class B Financial Statement Overview

Summary

The company's financial profile is highly mixed. It boasts a pristine, zero-debt balance sheet and an exceptional 90.3% gross profit margin. However, these structural strengths are heavily outweighed by persistent unprofitability, significant net losses (-52.4% net margin), and ongoing negative cash flow.

Income Statement

30Negative

Balance Sheet

75Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.21M	14.36M	14.91M	6.97M	4.67M	7.70M
Gross Profit	14.49M	-2.07M	14.14M	5.04M	5.17M	7.10M
EBITDA	-743.67K	-1.41M	6.82M	-13.53M	-25.77M	-18.34M
Net Income	-10.07M	-10.09M	5.77M	-22.71M	-29.46M	-20.08M
Balance Sheet
Total Assets	16.90M	16.90M	18.09M	21.41M	25.29M	29.68M
Cash, Cash Equivalents and Short-Term Investments	564.00K	907.00K	1.00M	1.52M	3.72M	9.48M
Total Debt	0	0	0	0	0	207.69K
Total Liabilities	6.84M	7.03M	6.29M	19.75M	18.22M	15.00M
Stockholders Equity	10.06M	9.88M	11.80M	1.66M	7.07M	14.68M
Cash Flow
Free Cash Flow	-444.79K	-1.35M	2.49M	-17.67M	-30.03M	-22.76M
Operating Cash Flow	-444.79K	675.00K	3.12M	-16.52M	-28.13M	-19.67M
Investing Cash Flow	-1.79M	-2.02M	-634.00K	-1.15M	-1.76M	-3.02M
Financing Cash Flow	1.25M	1.25M	-5.54M	15.47M	24.14M	6.85M

S2Medical AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:S2M against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:STIL	81Outperform	SEK 2.23B	23.04	―	―	28.75%	138.25%
SE:ALIF.B	74Outperform	SEK 22.23B	34.26	11.32%	0.83%	1.62%	63.45%
SE:ARJO.B	69Neutral	SEK 9.18B	26.50	4.65%	2.70%	-0.50%	-17.58%
SE:BACTI.B	53Neutral	SEK 560.70M	87.78	1.93%	―	-0.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SEDANA	49Neutral	SEK 926.81M	-27.17	-3.88%	―	0.42%	15.03%
SE:S2M	44Neutral	SEK 6.89M	-0.31	-101.03%	―	―	―

* Healthcare Sector Average

Performance Comparison

SE:S2M and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:S2M	S2Medical AB Class B	0.01	-0.00	-9.09%
SE:ALIF.B	AddLife AB Class B	180.20	-16.75	-8.51%
SE:ARJO.B	Arjo AB Class B	35.24	5.46	18.33%
SE:BACTI.B	Bactiguard Holding AB	15.80	-0.40	-2.47%
SE:SEDANA	Sedana Medical AB	9.44	-0.64	-6.35%
SE:STIL	Stille AB	247.00	70.50	39.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026

S2Medical AB Class B AI Stock Analysis